Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Impact of Mutations in Blood Cancer-Related Genes on Clinical Outcomes in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Tyrosine Kinase Inhibitors (TKIs) in the Ascembl Trial

Susan Branford, Andreas Hochhaus, Michael Mauro, Yosuke Minami, Delphine Rea, Carla Maria Boquimpani De Moura Freitas, Pablo Serrano-Fernandez, Vanessa Obourn, Andreas Bruederle, Noemi Espurz, Timothy P Hughes

Blood (2023) 142 (Supplement 1): 449.

https://doi.org/10.1182/blood-2023-187636

Published: 2023

Journal Articles

Neutralization of IL-1β and P-Selectin Inhibition Attenuate Organ Injury in Mice with Sickle Cell Disease

Erica M.F. Gotardo, Lucas F.S. Gushiken, Pamela L Brito, Flavia C. Leonardo, Lidiane S. Torres, Sergei Agoulnik, Jiri Kovarik, Andreas Bruederle, John Millholland, Fernando Ferreira Costa, Nicola Conran

Blood (2023) 142 (Supplement 1): 2487.

https://doi.org/10.1182/blood-2023-181895

Published: 2023

Journal Articles

Activation of Distinct Inflammatory Pathways in LR-MDS Is Determined By Genetics

Marie Schneider, Clara Rolfs, Matthias Trumpp, Susann Winter, Luise Fischer, Mandy Richter, Victoria Menger, Kolja Nenoff, Nora Grieb, Anne Sophie Kubasch, Klaus H. Metzeler, Katja Sockel, Christian Thiede, Lorenz C Hofbauer, Andreas Roth, Andreas Bruederle, Janghee Woo, Michael Cross, Uwe Platzbecker

Blood (2022) 140 (Supplement 1): 4011–4012.

https://doi.org/10.1182/blood-2022-163246

Published: 2022

Journal Articles

Reduction in Endothelial Adhesion of Red Blood Cells Under Crizanlizumab: Assessment of Standardized Microfluidic Platform in Sickle Cell Disease Population

Chiara Federici, Erdem Kucukal, Seniye Sertel, Gabrielle Combs, Karamoja Monchamp, Aaron Wolfe, Lalitha Nayak, Andreas Bruederle, John Zak, Umut A. Gurkan

Blood (2022) 140 (Supplement 1): 11106–11107.

https://doi.org/10.1182/blood-2022-169364

Published: 2022

Journal Articles

P-Selectin Blockage Potentiates the Inhibiting Effects of Inflammasome Cytokine Neutralization on Leukocyte Recruitment in an In Vivo Model of Acute Sickle Cell Vaso-Occlusion

Erica M.F. Gotardo, Lidiane S. Torres, Lucas F.S. Gushiken, Pamela L. Brito, Flavia C. Leonardo, Sergei Agoulnik, Jiri Kovarik, Andreas Bruederle, John Millholland, Alessandra Vitaliti, Irmgard Förster, Fernando Ferreira Costa, Nicola Conran

Blood (2022) 140 (Supplement 1): 8230–8232.

https://doi.org/10.1182/blood-2022-159020

Published: 2022

Journal Articles

Assessment of the Effect of Crizanlizumab on Red Blood Cell Adhesion to Endothelial Cells Using a Standardized Endothelium-on-a-Chip Microfluidic Platform

Erdem Kucukal, Aaron Wolfe, Ryan Kocevar, Lalitha V Nayak, Andreas Bruederle, John Zak, Umut A. Gurkan

Blood (2021) 138 (Supplement 1): 2021.

https://doi.org/10.1182/blood-2021-151695

Published: 2021

Journal Articles

Characterization of Two Anti-P-Selectin Monoclonal Antibodies (mAbs): Crizanlizumab Shows Comparable or Stronger Effects Versus Inclacumab across Cell Adhesion Assays in Vitro

Tina Rubic-Schneider, Prithu Sundd, David Ledieu, Déborah Garcia, Jeannine Hehlen, Coline Burnet-Merlin, Benjamin Cochin de Billy, Barbara Greutmann, Frieder Krӧner, Mélanie Verneret, Andreas Bruederle, Xiufeng Gao, Maya Dajee

Blood (2021) 138 (Supplement 1): 2032.

https://doi.org/10.1182/blood-2021-147318

Published: 2021

Journal Articles

Established Prevention of Vaso-Occlusive Crises with Crizanlizumab Is Further Improved in Patients Who Follow the Standard Treatment Regimen: Post-Hoc Analysis of the Phase II Sustain Study

Darla K Liles, MD, Rodolfo Cançado, Julie Kanter, MD, Abdullah Kutlar, MD, Andreas Bruederle, Michael Shi, MD PhD, Federico Campigotto, Kenneth I. Ataga

Blood (2018) 132 (Supplement 1): 1082.

https://doi.org/10.1182/blood-2018-99-112201

Published: 2018

Journal Articles

Crizanlizumab 5.0 Mg/Kg Increased the Time to First on-Treatment Sickle Cell Pain Crisis: A Subgroup Analysis of the Phase II Sustain Study

Julie Kanter, MD, Abdullah Kutlar, MD, Darla Liles, Rodolfo Cançado, Andreas Bruederle, Michael Shi, MD PhD, Zewen Zhu, Kenneth I Ataga, MD

Blood (2017) 130 (Supplement 1): 613.

https://doi.org/10.1182/blood.V130.Suppl_1.613.613

Published: 2017

Journal Articles

Predicting Serum Ferritin Levels in Patients with Iron Overload Treated with the Film-Coated Tablet of Deferasirox during the Eclipse Study

Ali Taher, MDPhDFRCP, Sebastian Weber, Jackie Han, Andreas Bruederle, John B. Porter, BA MB BChir MRCP(Path) FRCP(Path) MD

Blood (2017) 130 (Supplement 1): 3508.

https://doi.org/10.1182/blood.V130.Suppl_1.3508.3508

Published: 2017

Journal Articles

Long-Term Therapy with Deferasirox in Young Pediatric Patients with Transfusional Hemosiderosis Completing up to 5 Years of Treatment in the Observational E.N.T.R.U.S.T. Study

Elliott Vichinsky, Amal El-Beshlawy, Azzam Alzoebie, Annie Kamdem, MD, Suzanne Koussa, Thirachit Chotsampancharoen, Andreas Bruederle, Jackie Han, Mohsen Elalfy

Blood (2016) 128 (22): 2470.

https://doi.org/10.1182/blood.V128.22.2470.2470

Published: 2016

Journal Articles

Impact of Age and Type of Underlying Disease on Long-Term Safety and Efficacy in Patients with Transfusional Hemosiderosis Treated with Deferasirox: Results from a 3-Year Non-Interventional Study (SENTINEL)

Mohsen Elalfy, Baba Inusa, David Beneitez, Blanca Xicoy, MD, Maria Soledad Duran Nieto, Andreas Bruederle, Amin Azmon, Amal El-Beshlawy

Blood (2016) 128 (22): 4831.

https://doi.org/10.1182/blood.V128.22.4831.4831

Published: 2016

Journal Articles

Treatment Outcomes in Patients with Transfusional Hemosiderosis Who Received Deferasirox for up to 3 Years: Results from Sentinel Study

Mohsen Elalfy, Baba Inusa, David Beneitez, Blanca Xicoy, MD, Maria Soledad Duran Nieto, Andreas Bruederle, Amin Azmon, Amal El-Beshlawy

Blood (2016) 128 (22): 4834.

https://doi.org/10.1182/blood.V128.22.4834.4834

Published: 2016

NARROW

Impact of Mutations in Blood Cancer-Related Genes on Clinical Outcomes in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Tyrosine Kinase Inhibitors (TKIs) in the Ascembl Trial

Neutralization of IL-1β and P-Selectin Inhibition Attenuate Organ Injury in Mice with Sickle Cell Disease

Activation of Distinct Inflammatory Pathways in LR-MDS Is Determined By Genetics

Reduction in Endothelial Adhesion of Red Blood Cells Under Crizanlizumab: Assessment of Standardized Microfluidic Platform in Sickle Cell Disease Population

P-Selectin Blockage Potentiates the Inhibiting Effects of Inflammasome Cytokine Neutralization on Leukocyte Recruitment in an In Vivo Model of Acute Sickle Cell Vaso-Occlusion

Assessment of the Effect of Crizanlizumab on Red Blood Cell Adhesion to Endothelial Cells Using a Standardized Endothelium-on-a-Chip Microfluidic Platform

Characterization of Two Anti-P-Selectin Monoclonal Antibodies (mAbs): Crizanlizumab Shows Comparable or Stronger Effects Versus Inclacumab across Cell Adhesion Assays in Vitro

Established Prevention of Vaso-Occlusive Crises with Crizanlizumab Is Further Improved in Patients Who Follow the Standard Treatment Regimen: Post-Hoc Analysis of the Phase II Sustain Study

Crizanlizumab 5.0 Mg/Kg Increased the Time to First on-Treatment Sickle Cell Pain Crisis: A Subgroup Analysis of the Phase II Sustain Study

Predicting Serum Ferritin Levels in Patients with Iron Overload Treated with the Film-Coated Tablet of Deferasirox during the Eclipse Study

Long-Term Therapy with Deferasirox in Young Pediatric Patients with Transfusional Hemosiderosis Completing up to 5 Years of Treatment in the Observational E.N.T.R.U.S.T. Study

Impact of Age and Type of Underlying Disease on Long-Term Safety and Efficacy in Patients with Transfusional Hemosiderosis Treated with Deferasirox: Results from a 3-Year Non-Interventional Study (SENTINEL)

Treatment Outcomes in Patients with Transfusional Hemosiderosis Who Received Deferasirox for up to 3 Years: Results from Sentinel Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only